Tharimmune Appoints James Gordon Liddy as Strategic Advisor

Tharimmune Inc., a clinical-stage biopharmaceutical company, has appointed James Gordon Liddy, a renowned expert in counterterrorism and critical infrastructure protection, as a strategic advisor. Liddy will assist in the advancement of Tharimmune's lead program, TH104, aimed at providing temporary prophylaxis against opioid-induced respiratory or central nervous system depression in personnel exposed to high-potency opioids, including fentanyl.

With a background in national security, Liddy has crafted key strategies for combatting terrorism, lending his expertise to Tharimmune's initiatives. Tharimmune recently received positive feedback from the FDA on TH104, which they hope to advance without further clinical trials, using existing data for military and responder needs.

Liddy praised Tharimmune's commitment to tackling opioid threats, expressing enthusiasm for contributing to the company's strategic goals. His academic and professional qualifications further bolster his advisory role.